Auteurs : Langouo Fontsa M, Padonou F, Willard-Gallo K Année : 2022 Journal : Curr Opin Oncol
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.
Auteurs : Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A Année : 2022 Journal : Cancers (Basel)
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.
Auteurs : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M Année : 2022 Journal : Diagnostics (Basel)
T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.